Asia-Pacific genetic testing market is expected to reach USD 15,964,607.02 thousand by 2031 from USD 4,482,551.35 thousand in 2023 with growing at a CAGR of 17.5% during the forecast period of 2024 to 2031. Market Segmentation Asia-Pacific Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), By Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031 Overview of Global Genetic Testing Market Dynamics Driver • Growing prevalence of genetic disorders Restrain • High cost of genetic testing Opportunity • Strategic initiatives by the key market player Market Players Some of the key market players for Asia-Pacific genetic testing market are: • Thermo Fisher Scientific Inc. • Invitae Corporation • Bio-Rad Laboratories, Inc. • PerkinElmer Inc. • Illumina, Inc. • QIAGEN • F. Hoffmann-La Roche Ltd. • Fulgent Genetics • Myriad Genetics, Inc. • Abbott • Eurofins Scientific • Sorenson Genomics • BIO-HELIX • Biocartis • Cepheid (A subsidiary of Danaher) • PacBio • ELITechGroup • Genes2Me • Eugene Labs • Otogenetics • Mapmygenome • MedGenome • BioReference • Natera, Inc.

1 INTRODUCTION 67 1.1 OBJECTIVES OF THE STUDY 67 1.2 MARKET DEFINITION 67 1.3 OVERVIEW OF THE ASIA PACIFIC GENETIC TESTING MARKET 67 1.4 LIMITATIONS 69 1.5 MARKETS COVERED 69 2 MARKET SEGMENTATION 72 2.1 MARKETS COVERED 72 2.2 GEOGRAPHICAL SCOPE 73 2.3 YEARS CONSIDERED FOR THE STUDY 74 2.4 CURRENCY AND PRICING 74 2.5 DBMR TRIPOD DATA VALIDATION MODEL 75 2.6 TYPE LIFELINE CURVE 79 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80 2.8 DBMR MARKET POSITION GRID 81 2.9 MARKET APPLICATION COVERAGE GRID 82 2.10 VENDOR SHARE ANALYSIS 83 2.11 SECONDARY SOURCES 84 2.12 ASSUMPTIONS 84 3 EXECUTIVE SUMMARY 85 4 PREMIUM INSIGHTS 87 4.1 PESTAL ANALYSIS 90 4.2 PORTERS 5 FORCES 91 4.3 EPIDEMIOLOGY 92 5 ASIA PACIFIC GENETIC TESTING MARKET: REGULATIONS 93 6 MARKET OVERVIEW 95 6.1 DRIVERS 97 6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 97 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 97 6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 98 6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 98 6.2 RESTRAINTS 99 6.2.1 HIGH COST OF GENETIC TESTING 99 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 100 6.3 OPPORTUNITIES 100 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 100 6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 101 6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 101 6.4 CHALLENGES 102 6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 102 6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 103 7 ASIA PACIFIC GENETIC TESTING MARKET, BY TYPE 104 7.1 OVERVIEW 105 7.2 DIAGNOSTIC TESTING 109 7.3 PRENATAL TESTING 109 7.3.1 NON-INVASIVE SCREENING 110 7.3.1.1 WHOLE GENOME SEQUENCING 111 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 111 7.3.1.3 OTHERS 111 7.3.2 BY CONDITION 112 7.3.2.1 TRISOMY 21 112 7.3.2.2 KLINEFELTER SYNDROME 112 7.3.2.3 JACOBS SYNDROME 112 7.3.2.4 CYSTIC FIBROSIS 112 7.3.2.5 TURNER SYNDROME 113 7.3.2.6 TRISOMY 18 113 7.3.2.7 HEMOPHILIA 113 7.3.2.8 TRISOMY 13 113 7.3.2.9 MICRODELETION SYNDROME 113 7.3.2.10 FETAL GENDER 113 7.3.2.11 OTHERS 113 7.3.3 BY SCREENING TYPE 114 7.3.3.1 CARRIER SEQUENCING 114 7.3.3.2 SEQUENTIAL SEQUENCING 114 7.3.4 MATERNAL SERUM QUAD SCREENING 114 7.4 NEW-BORN SCREENING 115 7.4.1 SICKLE CELL DISEASE 115 7.4.2 CONGENITAL HYPOTHYROIDISM 116 7.4.3 PHENYLKETONURINA (PKU) 116 7.4.4 GALACTOSEMIA 116 7.4.5 MAPLE SYRUP URINE DISEASE 116 7.4.6 OTHERS 116 7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 116 7.6 CARRIER TESTING 117 7.6.1 MOLECULAR SCREENING TEST 117 7.6.2 BIOCHEMICAL SCREENING TEST 118 7.6.2.1 EXPANDED CARRIER SCREENING 118 7.6.2.2 PREDESIGNED PANEL TESTING 119 7.6.2.3 CUSTOM-MADE PANEL TESTING 119 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 119 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 119 7.6.2.4.2 PULMONARY CONDITIONS 120 7.6.2.4.3 NEUROLOGICAL CONDITIONS 120 7.6.2.4.4 OTHER CONDITIONS 120 7.7 OTHER TYPES 120 8 ASIA PACIFIC GENETIC TESTING MARKET, BY TECHNOLOGY 121 8.1 OVERVIEW 122 8.2 POLYMERASE CHAIN REACTION 125 8.2.1 REAL-TIME PCR (QPCR) 126 8.2.2 DIGITAL PCR (DPCR) 126 8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 126 8.2.4 HOT-START PCR 126 8.2.5 MULTIPLEX PCR 126 8.2.6 OTHER PCR 126 8.3 DNA SEQUENCING (NGS-BASED TESTING) 127 8.3.1 NEXT GENERATION SEQUENCING (NGS) 127 8.3.2 SANGER SEQUENCING (SINGLE GENE) 127 8.3.3 OTHER 128 8.4 WHOLE GENOME SEQUENCING 128 8.5 MICROARRAYS 128 8.5.1 DNA MICROARRAYS 129 8.5.2 PROTEIN MICROARRAYS 129 8.5.3 OTHER MICROARRAYS 129 8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 129 8.7 OTHERS 130 9 ASIA PACIFIC GENETIC TESTING MARKET, BY DISEASES 131 9.1 OVERVIEW 132 9.2 CANCER 135 9.2.1 BREAST 136 9.2.2 COLON 136 9.2.3 LUNG 136 9.2.4 PROSTATE 136 9.2.5 OTHERS 136 9.3 SICKLE CELL ANEMIA 137 9.4 THALASSEMIA 137 9.5 RARE GENETIC DISORDER 138 9.5.1 TRISOMY 21 138 9.5.2 MONOSOMY X 138 9.5.3 TRISOMY 13 139 9.5.4 MICRODELETION SYNDROME 139 9.5.5 TRISOMY 18 139 9.5.6 OTHERS 139 9.6 FRAGILE X SYNDROME 139 9.7 DUCHENNE MUSCULAR DYSTROPHY 140 9.8 HUNTINGTON'S DISEASE 140 9.9 CYSTIC FIBROSIS 141 9.10 OTHERS 141 10 ASIA PACIFIC GENETIC TESTING MARKET, BY END USER 142 10.1 OVERVIEW 143 10.2 HOSPITALS 146 10.3 CLINICS 147 10.4 DIAGNOSTIC CENTERS 147 10.5 PRIVATE CLINICS 148 10.6 LABORATORY SERVICE PROVIDERS 148 10.7 PRIVATE LABORATORIES 149 11 ASIA PACIFIC GENETIC TESTING MARKET, BY REGION 150 11.1 ASIA-PACIFIC 152 11.1.1 CHINA 161 11.1.2 JAPAN 172 11.1.3 INDIA 183 11.1.4 SOUTH KOREA 194 11.1.5 AUSTRALIA 205 11.1.6 SINAGPORE 216 11.1.7 THAILAND 227 11.1.8 INDONESIA 238 11.1.9 PHILIPPINES 249 11.1.10 MALAYSIA 260 11.1.11 VIETNAM 271 11.1.12 REST OF ASIA-PACIFIC 282 12 ASIA PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 283 12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 283 13 SWOT ANALYSIS 284 14 COMPANY PROFILES 285 14.1 ILLUMINA, INC 285 14.1.1 COMPANY SNAPSHOT 285 14.1.2 REVENUE ANALYSIS 285 14.1.3 COMPANY SHARE ANALYSIS 286 14.1.4 PRODUCT PORTFOLIO 286 14.1.5 RECENT DEVELOPMENT 287 14.2 CEPHEID 288 14.2.1 COMPANY SNAPSHOT 288 14.2.2 REVENUE ANALYSIS 288 14.2.3 COMPANY SHARE ANALYSIS 289 14.2.4 PRODUCT PORTFOLIO 289 14.2.5 RECENT DEVELOPMENT 289 14.3 FULGENT GENETICS 290 14.3.1 COMPANY SNAPSHOT 290 14.3.2 REVENUE ANALYSIS 290 14.3.3 COMPANY SHARE ANALYSIS 291 14.3.4 PRODUCT PORTFOLIO 291 14.3.5 RECENT DEVELOPMENT 292 14.4 PERKINELMER INC 293 14.4.1 COMPANY SNAPSHOT 293 14.4.2 REVENUE ANALYSIS 293 14.4.3 COMPANY SHARE ANALYSIS 294 14.4.4 PRODUCT PORTFOLIO 294 14.4.5 RECENT DEVELOPMENT 294 14.5 THERMO FISHER SCIENTIFIC INC 295 14.5.1 COMPANY SNAPSHOT 295 14.5.2 REVENUE ANALYSIS 295 14.5.3 COMPANY SHARE ANALYSIS 296 14.5.4 PRODUCT PORTFOLIO 296 14.5.5 RECENT DEVELOPMENT 297 14.5.5.1 COLLABORATION 297 14.6 BIOREFERENCE 298 14.6.1 COMPANY SNAPSHOT 298 14.6.2 REVENUE ANALYSIS 298 14.6.3 PRODUCT PORTFOLIO 299 14.6.4 RECENT DEVELOPMENT 299 14.7 ELITECHGROUP 300 14.7.1 COMPANY SNAPSHOT 300 14.7.2 PRODUCT PORTFOLIO 300 14.7.3 RECENT DEVELOPMENTS 301 14.8 EUROFINS SCIENTIFIC 302 14.8.1 COMPANY SNAPSHOT 302 14.8.2 REVENUE ANALYSIS 302 14.8.3 PRODUCT PORTFOLIO 303 14.8.4 RECENT DEVELOPMENT 303 14.9 INVITAE CORPORATION 304 14.9.1 COMPANY SNAPSHOT 304 14.9.2 REVENUE ANALYSIS 304 14.9.3 PRODUCT PORTFOLIO 305 14.9.4 RECENT DEVELOPMENTS 305 14.10 MYRIAD GENETICS 306 14.10.1 COMPANY SNAPSHOT 306 14.10.2 REVENUE ANALYSIS 306 14.10.3 PRODUCT PORTFOLIO 307 14.10.4 RECENT DEVELOPMENT 307 14.11 ABBOTT 308 14.11.1 COMPANY SNAPSHOT 308 14.11.2 REVENUE ANALYSIS 308 14.11.3 PRODUCT PORTFOLIO 309 14.11.4 RECENT DEVELOPMENT 309 14.12 BIOCARTIS 310 14.12.1 COMPANY SNAPSHOT 310 14.12.2 REVENUE ANALYSIS 310 14.12.3 PRODUCT PORTFOLIO 311 14.12.4 RECENT DEVELOPMENTS 311 14.12.4.1 PARTNERSHIP 311 14.13 BIO-HELIX 312 14.13.1 COMPANY SNAPSHOT 312 14.13.2 PRODUCT PORTFOLIO 312 14.13.3 RECENT DEVELOPMENT 312 14.14 BIO-RAD LABORATORIES, INC 313 14.14.1 COMPANY SNAPSHOT 313 14.14.2 REVENUE ANALYSIS 313 14.14.3 PRODUCT PORTFOLIO 314 14.14.4 RECENT DEVELOPMENTS 314 14.15 EUGENE LABS 315 14.15.1 COMPANY SNAPSHOT 315 14.15.2 PRODUCT PORTFOLIO 315 14.15.3 RECENT DEVELOPMENT 315 14.16 F. HOFFMANN-LA ROCHE LTD 316 14.16.1 COMPANY SNAPSHOT 316 14.16.2 REVENUE ANALYSIS (PARENT COMPANY) 316 14.16.3 PRODUCT PORTFOLIO 317 14.16.4 RECENT DEVELOPMENT 317 14.17 GENES2ME 318 14.17.1 COMPANY SNAPSHOT 318 14.17.2 PRODUCT PORTFOLIO 318 14.17.3 RECENT DEVELOPMENT 318 14.18 MAPMYGENOME 319 14.18.1 COMPANY SNAPSHOT 319 14.18.2 PRODUCT PORTFOLIO 319 14.18.3 RECENT DEVELOPMENT 320 14.19 MEDGENOME 321 14.19.1 COMPANY SNAPSHOT 321 14.19.2 PRODUCT PORTFOLIO 321 14.19.3 RECENT DEVELOPMENT 322 14.20 NATERA, INC 323 14.20.1 COMPANY SNAPSHOT 323 14.20.2 REVENUE ANALYSIS 323 14.20.3 PRODUCT PORTFOLIO 324 14.20.4 RECENT DEVELOPMENT 325 14.21 OTOGENETICS 326 14.21.1 COMPANY SNAPSHOT 326 14.21.2 PRODUCT PORTFOLIO 327 14.21.3 RECENT DEVELOPMENT 327 14.22 PACBIO 328 14.22.1 COMPANY SNAPSHOT 328 14.22.2 REVENUE ANALYSIS 328 14.22.3 PRODUCT PORTFOLIO 329 14.22.4 RECENT DEVELOPMENT 329 14.23 QIAGEN 330 14.23.1 COMPANY SNAPSHOT 330 14.23.2 REVENUE ANALYSIS 330 14.23.3 PRODUCT PORTFOLIO 331 14.23.4 RECENT DEVELOPMENT 331 14.24 SORENSON GENOMICS 332 14.24.1 COMPANY SNAPSHOT 332 14.24.2 PRODUCT PORTFOLIO 332 14.24.3 RECENT DEVELOPMENT 332 15 QUESTIONNAIRE 333 16 RELATED REPORTS 336